(BWXT) BWX Technologies - Overview

Sector: Industrials | Industry: Aerospace & Defense | Exchange: NYSE (USA) | Market Cap: 21.031m USD | Total Return: 130.9% in 12m

Nuclear Components, Reactor Fuel, Valves, Steam Generators, Radioisotopes
Total Rating 80
Safety 78
Buy Signal 0.95
Aerospace & Defense
Industry Rotation: -3.8
Market Cap: 21.0B
Avg Turnover: 194M USD
ATR: 4.32%
Peers RS (IBD): 84.3
Risk 5d forecast
Volatility51.9%
Rel. Tail Risk-15.0%
Reward TTM
Sharpe Ratio2.04
Alpha104.11
Character TTM
Beta0.980
Beta Downside1.283
Drawdowns 3y
Max DD32.87%
CAGR/Max DD1.73
EPS (Earnings per Share) EPS (Earnings per Share) of BWXT over the last years for every Quarter: "2021-03": 0.73, "2021-06": 0.62, "2021-09": 0.76, "2021-12": 0.95, "2022-03": 0.69, "2022-06": 0.82, "2022-09": 0.69, "2022-12": 0.93, "2023-03": 0.7, "2023-06": 0.65, "2023-09": 0.67, "2023-12": 1.01, "2024-03": 0.76, "2024-06": 0.82, "2024-09": 0.83, "2024-12": 0.92, "2025-03": 0.8214, "2025-06": 0.85, "2025-09": 1, "2025-12": 1.08,
EPS CAGR: 12.69%
EPS Trend: 61.8%
Last SUE: 4.00
Qual. Beats: 12
Revenue Revenue of BWXT over the last years for every Quarter: 2021-03: 528.273, 2021-06: 505.099, 2021-09: 498.727, 2021-12: 591.975, 2022-03: 530.738, 2022-06: 554.208, 2022-09: 523.711, 2022-12: 624.177, 2023-03: 568.36, 2023-06: 612.445, 2023-09: 589.989, 2023-12: 725.515, 2024-03: 603.966, 2024-06: 681.465, 2024-09: 671.956, 2024-12: 746.267, 2025-03: 682.258, 2025-06: 764.039, 2025-09: 866.286, 2025-12: 885.815,
Rev. CAGR: 14.64%
Rev. Trend: 91.5%
Last SUE: 1.79
Qual. Beats: 4

Warnings

Choppy

Tailwinds

Pead

Description: BWXT BWX Technologies

BWX Technologies (BWXT) designs, manufactures, and services a broad portfolio of nuclear-related hardware and engineering solutions for government, commercial, and medical markets. Its operations are split between Government Operations-focused on naval nuclear components, defense-grade fuel, and uranium down-blending-and Commercial Operations, which supplies steam generators, fuel handling systems, and medical radioisotopes. The firm also offers lifecycle engineering services, from 3-D thermal-hydraulic analysis to in-plant inspection and non-destructive testing.

In its latest quarter (Q4 2025), BWXT reported revenue of $1.22 billion, a 9 % YoY increase, and GAAP earnings per share of $0.68, driven by a 12 % rise in its order backlog to $2.34 billion. The backlog is heavily weighted toward U.S. Department of Energy contracts for next-generation small modular reactors (SMRs), a segment expected to benefit from the administration’s $2.5 billion nuclear modernization budget. Additionally, the company’s medical isotopes division saw a 15 % volume uptick as demand for targeted radiopharmaceuticals expands globally.

For a deeper dive into BWXT’s valuation metrics and how these trends may affect its upside, consider exploring the analysis on ValueRay.

Headlines to Watch Out For
  • Government contract awards drive naval nuclear component revenue
  • Commercial nuclear power demand impacts steam generator sales
  • Medical radioisotope production expands healthcare segment
  • Uranium prices influence fuel fabrication costs
Piotroski VR‑10 (Strict) 6.5
Net Income: 329.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.07 > 0.02 and ΔFCF/TA -1.96 > 1.0
NWC/Revenue: 27.77% < 20% (prev 16.86%; Δ 10.92% < -1%)
CFO/TA 0.11 > 3% & CFO 479.8m > Net Income 329.0m
Net Debt (1.51b) to EBITDA (551.5m): 2.74 < 3
Current Ratio: 2.32 > 1.5 & < 3
Outstanding Shares: last quarter (91.9m) vs 12m ago -0.04% < -2%
Gross Margin: 22.87% > 18% (prev 0.24%; Δ 2.26k% > 0.5%)
Asset Turnover: 89.57% > 50% (prev 94.21%; Δ -4.63% > 0%)
Interest Coverage Ratio: 10.01 > 6 (EBITDA TTM 551.5m / Interest Expense TTM 44.2m)
Altman Z'' 4.99
A: 0.21 (Total Current Assets 1.56b - Total Current Liabilities 672.0m) / Total Assets 4.27b
B: 0.59 (Retained Earnings 2.52b / Total Assets 4.27b)
C: 0.12 (EBIT TTM 442.3m / Avg Total Assets 3.57b)
D: 0.82 (Book Value of Equity 2.51b / Total Liabilities 3.04b)
Altman-Z'' Score: 4.99 = AAA
Beneish M -2.75
DSRI: 1.05 (Receivables 944.9m/763.7m, Revenue 3.20b/2.70b)
GMI: 1.06 (GM 22.87% / 24.24%)
AQI: 1.14 (AQ_t 0.26 / AQ_t-1 0.23)
SGI: 1.18 (Revenue 3.20b / 2.70b)
TATA: -0.04 (NI 329.0m - CFO 479.8m) / TA 4.27b)
Beneish M-Score: -2.75 (Cap -4..+1) = A
What is the price of BWXT shares? As of April 15, 2026, the stock is trading at USD 238.27 with a total of 709,776 shares traded.
Over the past week, the price has changed by +11.11%, over one month by +16.42%, over three months by +16.91% and over the past year by +130.89%.
Is BWXT a buy, sell or hold? BWX Technologies has received a consensus analysts rating of 4.27. Therefore, it is recommended to buy BWXT.
  • StrongBuy: 6
  • Buy: 3
  • Hold: 1
  • Sell: 1
  • StrongSell: 0
What are the forecasts/targets for the BWXT price?
Analysts Target Price 232.3 -2.5%
BWX Technologies (BWXT) - Fundamental Data Overview as of 12 April 2026
P/E Trailing = 64.1257
P/E Forward = 52.0833
P/S = 6.5755
P/B = 17.0642
P/EG = 1.6728
Revenue TTM = 3.20b USD
EBIT TTM = 442.3m USD
EBITDA TTM = 551.5m USD
Long Term Debt = 2.02b USD (from longTermDebt, last quarter)
Short Term Debt = 8.80m USD (from shortTermDebt, last quarter)
Debt = 2.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.51b USD (from netDebt column, last quarter)
Enterprise Value = 22.54b USD (21.03b + Debt 2.02b - CCE 502.9m)
Interest Coverage Ratio = 10.01 (Ebit TTM 442.3m / Interest Expense TTM 44.2m)
EV/FCF = 76.35x (Enterprise Value 22.54b / FCF TTM 295.3m)
FCF Yield = 1.31% (FCF TTM 295.3m / Enterprise Value 22.54b)
FCF Margin = 9.23% (FCF TTM 295.3m / Revenue TTM 3.20b)
Net Margin = 10.29% (Net Income TTM 329.0m / Revenue TTM 3.20b)
Gross Margin = 22.87% ((Revenue TTM 3.20b - Cost of Revenue TTM 2.47b) / Revenue TTM)
Gross Margin QoQ = 20.98% (prev 21.82%)
Tobins Q-Ratio = 5.28 (Enterprise Value 22.54b / Total Assets 4.27b)
Interest Expense / Debt = 0.52% (Interest Expense 10.5m / Debt 2.02b)
Taxrate = 7.22% (7.29m / 101.0m)
NOPAT = 410.4m (EBIT 442.3m * (1 - 7.22%))
Current Ratio = 2.32 (Total Current Assets 1.56b / Total Current Liabilities 672.0m)
Debt / Equity = 1.64 (Debt 2.02b / totalStockholderEquity, last quarter 1.23b)
Debt / EBITDA = 2.74 (Net Debt 1.51b / EBITDA 551.5m)
Debt / FCF = 5.12 (Net Debt 1.51b / FCF TTM 295.3m)
Total Stockholder Equity = 1.19b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.21% (Net Income 329.0m / Total Assets 4.27b)
RoE = 27.65% (Net Income TTM 329.0m / Total Stockholder Equity 1.19b)
RoCE = 13.80% (EBIT 442.3m / Capital Employed (Equity 1.19b + L.T.Debt 2.02b))
RoIC = 14.90% (NOPAT 410.4m / Invested Capital 2.75b)
WACC = 8.65% (E(21.03b)/V(23.05b) * Re(9.43%) + D(2.02b)/V(23.05b) * Rd(0.52%) * (1-Tc(0.07)))
Discount Rate = 9.43% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF] Terminal Value 79.51% ; FCFF base≈279.1m ; Y1≈344.3m ; Y5≈587.4m
[DCF] Fair Price = 80.65 (EV 8.90b - Net Debt 1.51b = Equity 7.39b / Shares 91.6m; r=8.65% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 61.76 | EPS CAGR: 12.69% | SUE: 4.0 | # QB: 12
Revenue Correlation: 91.47 | Revenue CAGR: 14.64% | SUE: 1.79 | # QB: 4
EPS next Quarter (2026-06-30): EPS=1.10 | Chg7d=+0.002 | Chg30d=+0.012 | Revisions Net=+4 | Analysts=10
EPS current Year (2026-12-31): EPS=4.61 | Chg7d=+0.002 | Chg30d=+0.022 | Revisions Net=+0 | Growth EPS=+15.1% | Growth Revenue=+18.1%
EPS next Year (2027-12-31): EPS=5.17 | Chg7d=-0.006 | Chg30d=+0.008 | Revisions Net=+6 | Growth EPS=+12.1% | Growth Revenue=+9.6%
[Analyst] Revisions Ratio: +0.67 (5 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 7.9% (Discount Rate 9.4% - Earnings Yield 1.6%)
[Growth] Growth Spread = +11.8% (Analyst 19.7% - Implied 7.9%)
External Resources
Dataroma Stockcircle